Morphin 60 Retard (Morphine Sulfate)

Morphine sulfate, the active ingredient in Morphin 60 Retard, is an opioid analgesic presented as a 60 mg extended‑release tablet for oral use. It is a Schedule II controlled substance that provides analgesia for moderate to severe acute pain, chronic cancer pain, and post‑operative pain in adult patients.

GNH USA supplies Morphin 60 Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards. The product is available in bulk and individual packaging to meet diverse procurement needs.

Morphin 60 Retard, an opioid analgesic, is indicated for pain conditions managed through the central nervous system opioid pathway. - Moderate to severe acute pain: provides rapid, potent analgesia for short‑term severe pain episodes such as injury or acute medical conditions. - Chronic cancer pain: offers sustained, around‑the‑clock pain control for patients with malignant disease, helping to improve quality of life during ongoing treatment. - Post‑operative pain: maintains steady analgesia throughout the postoperative recovery period, reducing the need for frequent dosing and supporting early mobilization after surgery.

Morphin 60 Retard may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of queasiness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dry mouth: reduced salivation causing throat discomfort. - Sweating: excessive perspiration unrelated to temperature. - Dizziness: sensation of light‑headedness or imbalance.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Opioid dependence or addiction: compulsive use despite harmful consequences. - Adrenal insufficiency: inadequate cortisol production leading fatigue and weakness. - Serotonin syndrome: potentially fatal reaction when combined with serotonergic agents. - Anaphylaxis: severe allergic reaction with hives, swelling, and airway compromise.

When prescribing Morphin 60 Retard, clinicians should observe specific precautions to minimize risks and ensure safe use. - Assess pain severity and opioid tolerance: evaluate patient’s pain level and prior opioid exposure before initiating therapy. - Avoid use in respiratory compromise: contraindicated in patients with severe asthma, COPD, or sleep apnea. - Monitor for sedation and CNS depression: watch for excessive drowsiness, especially when combined with other CNS depressants. - Adjust dose in renal or hepatic impairment: start with lower doses and titrate cautiously in organ dysfunction. - Educate about constipation management: implement prophylactic laxatives and bowel regimen. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Morphin 60 Retard interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - CNS depressants (benzodiazepines, barbiturates, alcohol): may cause profound sedation and respiratory depression. - MAO inhibitors: risk of severe opioid toxicity and serotonin syndrome. - CYP3A4 inhibitors (ketoconazole, erythromycin): increase morphine plasma levels, heightening overdose risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce efficacy by lowering morphine concentrations. - Serotonergic agents (SSRIs, SNRIs, tramadol): may increase risk of serotonin syndrome. - Diuretics: may enhance hypotensive effects.